Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

FORMA Therapeutics Appoints Karoline Shair, Ph.D., J.D., Vice President, Legal and Chief Intellectual Property Counsel

FORMA Therapeutics
Posted on: 30 Aug 16

WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics, a clinical-stage and fully integrated research and development company, today announced the appointment of Karoline Shair, Ph.D., J.D., as Vice President, Legal and Chief Intellectual Property Counsel. Karoline joins the FORMA leadership team with over 20 years’ global experience in the biotechnology and pharmaceutical sector. She most recently served as Vice President and IP Region Head, at Takeda Pharmaceuticals International Co., in Cambridge, Massachusetts.

“Karoline’s expertise in the creation and implementation of global patent strategies, including patent listing, extension, data exclusivity and market protection strategies for drug products provides FORMA with proven IP leadership as we continue to expand our clinical portfolio. Further, her strength in litigation, licensing transactions and establishing high value relationships with collaborators is ideally suited for having a broad and immediate impact within FORMA’s business operations,” said Rob Sarisky, Ph.D., Chief Business Officer, FORMA Therapeutics. “Throughout her career, Karoline has demonstrated an exemplary commitment to raising awareness of innovation in human health care and the importance of IP protection in fueling future medical advances.”

Karoline Shair, Ph.D., J.D. noted, “I’m thrilled to join FORMA, a truly unique company that has the potential to make a fundamental change in the treatment of cancer and other serious diseases. The dynamic culture of the employees, the breadth of the therapeutic pipeline, and their distinct collaborative model to connect people and ideas, sets FORMA apart from its peers and captured my interest.”

“Karoline’s broad experiences in creating, protecting and enforcing IP rights for small molecules, biologics and other therapeutic modalities, as well as her operational leadership in establishing relevant policies and publication processes will have a tremendous impact at FORMA,” stated Steve Tregay, Ph.D., President and CEO, FORMA Therapeutics. “We welcome Karoline to the FORMA team and believe her contributions will be invaluable as we advance our medicines through key research and development milestones.”

Prior to joining FORMA, Karoline held various leadership positions at Millennium and Takeda from 2004 to 2016. Most recently as Vice President and IP Region Head, she was responsible for IP strategy and enforcing the Oncology IP portfolio for research, development and commercial operations. During that time, she provided strategic IP leadership leading a global team and working extensively with cross-functional teams to build, develop and preserve patent portfolios in inflammation and oncology. Prior to Millennium, Karoline gained relevant bench experience designing novel drug candidates at Sloan Kettering Institute for Cancer Research and Ariad Pharmaceuticals, as well as began her foundational training in IP at Choate, Hall & Stewart and Vertex in various legal roles.

Karoline received a bachelor’s degree with honors in chemistry from Bryn Mawr College, Bryn Mawr, Pennsylvania, a Ph.D. in chemistry from Yale University, New Haven, Connecticut and a J.D. from Boston College Law School, Newton, Massachusetts. Karoline is a member of the Massachusetts Bar and a registered patent attorney with the United States Patent and Trademark Office.


FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates that will ultimately provide profound patient benefit.

FORMA is headquartered in Watertown, Massachusetts near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, Connecticut.

Join our conversation on Twitter @FORMAInc.


Media Contact
For FORMA Therapeutics
Kari Watson, +1 781-235-3060
MacDougall Biomedical Communications

For more information:

Editor's Details

Mike Wood

Last updated on: 30/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.